Mathematical modelling company Physiomics, which specialises in the development of oncology drugs and personalised medicine, confirmed a renewed contract with Numab Therapeutics on Tuesday.
NM26-2198 is a first-in-class bi-specific antibody designed to simultaneously block multiple targets for the treatment of moderate to severe atopic dermatitis (AD) Combined single ascending dose
Numab Therapeutics AG ("Numab") and Ono Pharmaceutical Co., Ltd. ("Ono") today announced that Ono has exercised its option to enter into a development and license agreement for a multispecific antibody
Numab Therapeutics AG (Numab) and 3SBio Inc. ("3SBio", HKEX:1530) announced today that 3SBio's subsidiary Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. ("Sunshine Guojian") exercised its option